NEW YORK (GenomeWeb News) – Circulating tumor cell-based diagnostics firm Epic Sciences today announced an agreement with Laboratory Corporation of America aimed at speeding up sample processing for Epic's technology in support of European clinical trials.

LabCorp's Central Laboratory in Mechelen, Belgium will process samples for Epic's clinical trial partners and customers as part of the deal. The samples will then be sent to Epic's laboratory in La Jolla, Calif. for downstream detection and molecular characterization of CTCs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.